standalone not FDA-approved
Clinical manifestations
Citation72,Citation8184 Generally, to optimize and maintain product quality and safety during drug development, scientists must adjust and define the composition of the DP solution, which may contain buffer, pH, tonicity modifiers, anti-oxidants, surfactants, stabilizers, and viscosity-reducing additives
declares consultancy roles for Abbvie, Accutar Biotech, Allorion Therapeutics, AstraZeneca, Bayer, Biocartis, Boehringer Ingelheim, Chugai Pharmaceuticals, Daiichi Sankyo, DualityBio, Eisai, Eli Lilly, Frontier Medicines, Hongyun Biotechnology, Merus, Mirati Therapeutics, Monte Rosa, Novartis, Nuvalent, Pfizer, Roche/Genentech, Sanofi, Scorpion Therapeutics, SFJ Pharmaceuticals, Silicon Therapeutics, Syndax, Takeda Oncology, Transcenta and Voronoi
And if the PA is so far advanced that there is no intrinsic factor left, the antibodies can disappear
This ongoing oxidative stress leaves endothelial cells (the lining of blood vessels) highly vulnerable to ongoing damage, contributing to the micro-clotting and "immunothrombosis" frequently observed in Long Haulers